Since 2015, the US Food and Drug Administration (FDA) has granted 35 accelerated approvals to programmed cell death 1 (PD-1) and/or PD-1 ligand 1 (PD-L1) inhibitors, or just under half of the total (76) approvals for this class of medications.1 Of the 35 approvals, 10 were considered “dangling,” with postmarketing trials failing to meet key end points to confirm benefit for patients.2 Four of these 10 indications were withdrawn voluntarily by the pharmaceutical sponsors, leaving 6 for review by the FDA’s Oncologic Drugs Advisory Committee (ODAC).1 The ODAC voted on April 27 to 29, 2021, to keep 4 of the 6 remaining indications on the market.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Powell K, Lythgoe MP, Prasad V. The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval. JAMA Oncol. 2021;7(11):1607–1609. doi:10.1001/jamaoncol.2021.3046
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.